AMAG submits sNDA for subcutaneous Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) submitted an sNDA to FDA for subcutaneous Makena hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women who spontaneously delivere...